ArticleClinical rheumatology2023
Age, body mass index, and function as the independent predictors of sarcopenia in axial spondyloarthritis: a cross-sectional analysis.
Article in Clinical rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Is sarcopenia a real concern in ankylosing spondylitis? A systematic literature review.European geriatric medicine · 2024Pooled it
- Article
- Association between sarcopenia and physical activity in individuals with spondyloarthritis.Journal of rheumatic diseases · 2025Article
- Body composition, bone mineral density, and functional impairment in axial spondyloarthritis: a 36-month longitudinal study.BMC musculoskeletal disorders · 2025Article
- Sarcopenia in Rheumatic Diseases: A Hidden Issue of Concern.Diseases (Basel, Switzerland) · 2025Review
- Assessing Sarcopenia, Presarcopenia, and Malnutrition in Axial Spondyloarthritis: Insights from a Spanish Cohort.Nutrients · 2025Article
- Assessment of sarcopenia in young patients with inflammatory arthritis: a cross-sectional study.Scientific reports · 2025Article
- Screening and diagnosis of sarcopenia in rheumatic and musculoskeletal diseases: findings from a cross-sectional study.Rheumatology international · 2025Article
- Personalised screening tool for early detection of sarcopenia in stroke patients: a machine learning-based comparative study.Aging clinical and experimental research · 2025Article
- Genetic Influence of the Brain on Muscle Structure: A Mendelian Randomization Study of Sarcopenia.Journal of cachexia, sarcopenia and muscle · 2025Article
- Muscle health in ankylosing spondylitis: effects of disease duration, inflammation, education level, and spinal mobility on skeletal muscle atrophy.Therapeutic advances in musculoskeletal disease · 2025Article
- Comment on 'Age, body mass index, and function as the independent predictors of sarcopenia in axial spondyloarthritis: a cross-sectional analysis'.Clinical rheumatology · 2024Article
- Rebuttal on the comment on "Age, body mass index, and function as the independent predictors of sarcopenia in axial spondyloarthritis: a cross-sectional analysis".Clinical rheumatology · 2024Article
- Comparative evaluation of screening tools for sarcopenia in patients with axial spondyloarthritis.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveSarcopenia is characterized by a decline in muscle strength, muscle mass, and physical performance. Persistent inflammation may lead to muscle wasting. This research aims to determine the prevalence and associated factors of sarcopenia in axial spondyloarthritis (ax-SpA).
methodA cross-sectional study of 104 ax-SpA patients who met the 2009 ASAS criteria was conducted at Phramongkutklao Hospital between January 2020 and February 2021. Sarcopenia-related factors and disease characteristics were recorded. Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia 2019. Appendicular skeletal muscle mass was measured by dual-energy X-ray absorptiometry. Strength, ambulation, rising from a chair, stair climbing and history of falling (SARC-F) was evaluated. Muscle strength was measured by hand grip strength and chair stand time. Physical performance was assessed by 6-m walk and time up and go tests. Logistic regression was performed to identify factors associated with sarcopenia.
resultsMost patients were male (74%), with a mean (standard deviation, SD) age and disease duration of 42.6 (12.2) and 8.3 (8.5) years, respectively. The mean BMI (SD) was 23.8 (4.4). The prevalence of sarcopenia was 22.1%. There were no differences in disease activity (BASDAI and ASDAS) between ax-SpA patients with and without sarcopenia. Age, low BMI, and BASFI score were independently associated with sarcopenia, with adjusted odds ratios and 95% confidence intervals of 1.08 (1.01-1.16), 0.39 (0.25-0.63), and 1.41 (1.07-1.86), respectively.
conclusionSarcopenia is common in ax-SpA patients and is independently associated with older age, low BMI, and high BASFI score but not disease activity. Key Points • Despite the fact that ax-SpA patients are typically young, sarcopenia is frequently observed within this population. • Sarcopenia in ax-SpA patients has an independent association with older age, low BMI, and functional limitations (high BASFI scores). • Sarcopenia in ax-SpA patients is not associated with disease activity; however, early treatment to prevent functional limitations may prevent sarcopenia in ax-SpA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.